文献速递中医内科中药与中成药合理使用

加减消风散治疗慢性荨麻疹的随机双盲安慰剂对照研究方案

Efficacy and safety of modified Xiao-Feng Powder in the treatment of chronic urticaria: protocol of a randomized double-blind placebo-controlled study.
PubMed 文献 · Chin Med · 2022-07-22

本研究为随机双盲安慰剂对照试验方案,计划纳入58例中重度慢性荨麻疹患者(UAS>10),随机分为加减消风散联合比拉斯汀组与安慰剂联合比拉斯汀组,疗程12周,随访至第16周。主要结局为第12周UAS7变化,次要结局包括UCT、VAS瘙痒、CU-Q2oL、AAS、IgE、肠道菌群及抗组胺药使用。研究将在香港三家中医诊所开展。

要点

  • 加减消风散联合比拉斯汀治疗慢性荨麻疹的疗效与安全性尚待本试验验证。
  • 主要结局为第12周UAS7变化,次要结局涵盖UCT、VAS、CU-Q2oL、AAS、IgE及肠道菌群。
  • 本试验为中西医结合设计,受试者允许同时使用中药与西药。

核心结论

  • 本试验旨在为加减消风散治疗慢性荨麻疹的疗效与安全性提供临床证据。

研究设计与样本

  • 随机双盲安慰剂对照临床试验,计划招募58例轻至重度荨麻疹患者(UAS大于10)。
  • 受试者随机分为两组,均接受抗组胺药比拉斯汀,并分别联合加减消风散或安慰剂治疗12周,第16周随访。
  • 试验在香港三家中医诊所开展,注册号NCT04967092。

关键数值与推荐

  • 主要结局指标为第12周每周荨麻疹活动度评分(UAS7)的变化。
  • 次要结局包括荨麻疹控制试验(UCT)、瘙痒严重程度视觉模拟量表(VAS)、慢性荨麻疹生活质量问卷(CU-Q2oL)、血管性水肿活动度评分(AAS)、免疫球蛋白E(IgE)检测、肠道菌群检测及研究期间抗组胺药使用情况。
  • 纳入标准为荨麻疹活动度评分大于10的轻至重度患者。

临床怎么用

  • 本方案为研究设计,尚不能提供临床用药推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic Urticaria (CU), a common skin disorder known as Yin Zhen in Chinese medicine, is characterized by recurrent, pruritic, pink-to-red edematous lesions and wheals on the skin. Xiao-Feng Powder (XFP, meaning Wind-Dispersing Powder), is reported to be one of the most frequently used Chinese herbal formulae for CU. In this study, we aim to investigate the effectiveness and safety of modified Xiao-Feng Powder (mXFP) for the treatment of CU. METHODS: In this randomised double-blind placebo-controlled clinical trial, 58 subjects identified as having mild to severe urticaria (Urticaria activity score greater than 10) will be recruited and randomised into two groups to receive antihistamine Bilastine with either mXFP or placebo for 12 weeks, followed by post treatment visits at week 16. The primary outcome measure is the change of weekly urticaria activity score (UAS7) at week 12. Secondary outcome measures include the Urticaria Control Test (UCT), Visual Analog Scale of Itch Severity (VAS), Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL), Angioedema Activity Score (AAS), immunoglobulin E (IgE) test, gut microbiota test and use of antihistamines during study period. The trial will be conducted at three Chinese medicine clinics in Hong Kong. EXPECTED OUTCOMES: The results of this study will establish robust clinical evidence about the efficacy and safety of mXFP in the treatment of CU. A specific feature of this trial is that it is a integrative medicine trial with subjects being allowed to take the Western and Chinese medicine together for the treatment. Trial registration This is registered on ClinicalTrials.gov, ID: NCT04967092. Register date: July 19, 2021. https://clinicaltrials.gov/ct2/show/NCT04967092 .

来源:Chin Med,查看原文。版权归原作者所有。

引用

  1. Hung HY, Song T, Loo SKF, et al. Efficacy and safety of modified Xiao-Feng Powder in the treatment of chronic urticaria: protocol of a randomized double-blind placebo-controlled study. Chin Med. 2022. PMID: 35869554. doi:10.1186/s13020-022-00642-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。